The Evolving Role of Orexin-Based Therapy in Narcolepsy Type 1 Management

Program Overview

This CE activity was designed to improve learners’ knowledge and competence in relation to the management of patients with NT1.

Credit Expired
0.75 CE Credit(s)
Expires: December 1, 2022

Target Audience

This activity is intended for neurology and primary care clinicians involved in the treatment of narcolepsy type 1 (NT1).

Educational Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Recognize contemporary challenges in the management of narcolepsy type 1 (NT1)
  • Evaluate the role of orexin in the underlying pathophysiology of NT1
  • Analyze available data on emerging orexin-based therapies for the treatment of NT1
  • Identify patients with NT1 who might derive benefit from treatment with orexin-based therapy

Activity Faculty

Thorpy 300x400

Michael J. Thorpy, MD

Professor, Neurology
Albert Einstein College of Medicine
Bronx, New York, United States

Dauvilliers 300x400

Yves Dauvilliers, MD, PhD

Professor, Neurology and Physiology
Sleep Unit, Gui de Chauliac Hospital
University of Montpellier
Montpellier, France

Scammell 300x400

Thomas E. Scammell, MD

Professor, Neurology
Harvard Medical School
Beth Israel Deaconess Medical Center
Boston Children’s Hospital
Boston, Massachusetts, United States

The Evolving Role of Orexin-Based Therapy in Narcolepsy Type 1 Management


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources